Post‐radiotherapy cribriform‐morular thyroid carcinoma

Background According to the new 2022 World Health Organization classification of endocrine tumors, thyroid malignancy, formerly known as the cribriform‐morular variant of papillary thyroid carcinoma, is now categorized as differentiated thyroid malignancy; it is, at present, called cribriform‐morula...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical laboratory analysis 2023-01, Vol.37 (1), p.e24819-n/a
Main Authors: Or Koca, Arzu, Güler Şimşek, Gülçin
Format: Article
Language:English
Subjects:
Adolescent
Cellular biology
Classification
cribriform‐morular thyroid carcinoma
Cytokeratin
Cytoplasm
Endocrine system
Histogenesis
Hodgkin's lymphoma
Humans
Hypothyroidism
Lymphatic system
Lymphoma
Malignancy
Mutation
Neck
Papillary thyroid carcinoma
Pathology
Patients
post‐radiotherapy thyroid carcinoma
Radiation therapy
Thoracic surgery
Thyroid
Thyroid cancer
Thyroid Cancer, Papillary - pathology
Thyroid Cancer, Papillary - radiotherapy
thyroid carcinoma
Thyroid Neoplasms - pathology
Tumors
β-Catenin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background According to the new 2022 World Health Organization classification of endocrine tumors, thyroid malignancy, formerly known as the cribriform‐morular variant of papillary thyroid carcinoma, is now categorized as differentiated thyroid malignancy; it is, at present, called cribriform‐morular thyroid carcinoma and classified as a tumor of unknown histogenesis. Case Report In this case report, we report on a 15‐year‐old patient who underwent external radiotherapy to the neck for Hodgkin's disease and developed cribriform‐morular thyroid carcinoma 5 years after radiotherapy. Conclusions We believe that cribriform‐morular thyroid carcinoma with diffuse nuclear beta‐catenin expression has exciting and unresolved uncertainties that may affect disease prognosis and follow‐up for cytopathologists and endocrinologists.
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.24819